HIV patients pause meds in closely watched study
NCT ID NCT04359186
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study pauses HIV medication in 40 volunteers to closely monitor how the virus and body interact during the earliest stages of rebound. Participants stop their antiretroviral therapy and undergo frequent testing, resuming treatment within three weeks. The goal is to learn more about HIV persistence, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal how HIV rebounds after stopping medication, guiding future strategies for long-term remission.
- What could go wrong
- This is a small, early-stage observational study with no direct treatment benefit. Participants may experience virus rebound or side effects from stopping therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a robot help stroke survivors with HIV walk again?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a Father-Focused program curb HIV, substance abuse, and violence?
- Smart pill bottles and health coaches team up to tackle HIV in the deep south